{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:29:12Z","timestamp":1772162952972,"version":"3.50.1"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","award":["G.0692.14N"],"award-info":[{"award-number":["G.0692.14N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HIVERA","award":["249697"],"award-info":[{"award-number":["249697"]}]},{"name":"GHTM-UID","award":["04413"],"award-info":[{"award-number":["04413"]}]},{"name":"MigrantHIV","award":["7066"],"award-info":[{"award-number":["7066"]}]},{"name":"INTEGRIV","award":["31990"],"award-info":[{"award-number":["31990"]}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["PF\/10\/018"],"award-info":[{"award-number":["PF\/10\/018"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Viral pathogens causing global disease burdens are often characterized by high rates of evolutionary changes. The extensive viral diversity at baseline can shorten the time to escape from therapeutic or immune selective pressure and alter mutational pathways. The impact of genotypic background on the barrier to resistance can be difficult to capture, particularly for agents in experimental stages or that are recently approved or expanded into new patient populations.<\/jats:p>","DOI":"10.1128\/aac.00539-19","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:56:32Z","timestamp":1558583792000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors"],"prefix":"10.1128","volume":"63","author":[{"given":"Kristof","family":"Theys","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Laboratory Clinical and Evolutionary Virology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"}]},{"given":"Pieter J. K.","family":"Libin","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Laboratory Clinical and Evolutionary Virology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"},{"name":"Artificial Intelligence Lab, Department of Computer Science, Vrije Universiteit Brussel, Brussels, Belgium"}]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Laboratory Clinical and Evolutionary Virology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium"}]},{"given":"Ana B.","family":"Abecasis","sequence":"additional","affiliation":[{"name":"Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0148-6"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/v7092857"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000360947"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/135965350801300316","article-title":"Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response","volume":"13","author":"Deforche K","year":"2008","unstructured":"Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM, EuroSIDA Study Group. 2008. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther 13:399\u2013407.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-409"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003203"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.08.004"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.844649"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30317-5"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/135965350601100512","article-title":"Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02AG","volume":"11","author":"Abecasis AB","year":"2006","unstructured":"Abecasis AB, Deforche K, Bacheler LT, McKenna P, Carvalho AP, Gomes P, Vandamme AM, Camacho RJ. 2006. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02AG. Antivir Ther 11:581\u2013589.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01668-12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2993-2998.2004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v10010041"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir025"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.06.047"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0123"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-74"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01535-07"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-149"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes","volume":"14","author":"Ma\u00efga AI","year":"2009","unstructured":"Ma\u00efga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cisse M, Katlama C, Calvez V, Marcelin AG. 2009. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther 14:123\u2013129.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.07.311"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000209899.05126.e4"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/vex013"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206234"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2017.02.002"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099390"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/vex003"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy332"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy436"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001978"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011505"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061436"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy329"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit345"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-81"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.12.001"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2018-0060"},{"key":"e_1_3_3_43_2","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer RW","year":"2008","unstructured":"Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10:67\u201384.","journal-title":"AIDS Rev"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.2217\/hiv.09.40"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/v9110330"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1419"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.07133-11"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty851"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2013.04.032"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp455"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt162"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","article-title":"A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients","volume":"7","author":"Van Laethem K","year":"2002","unstructured":"Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. 2002. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 7:123\u2013129.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.41.6.2792-2794.2003"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200308150-00008"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007420"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00539-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00539-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T09:27:18Z","timestamp":1663493238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00539-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1128\/AAC.00539-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00539-19","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/647297","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2019-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00539-19"}}